Literature DB >> 8100915

Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease.

F G Fowkes1, G D Lowe, E Housley, A Rattray, A Rumley, R A Elton, I R MacGregor, J Dawes.   

Abstract

Haemostatic and rheological factors may predict cardiovascular disease. We studied patients with intermittent claudication to see if the progression of peripheral arterial disease and the risks of coronary events could be predicted by baseline packed cell volume, plasma fibrinogen, blood and plasma viscosites, von Willebrand factor antigen, cross-linked fibrin degradation products (XLFDP), urinary fibrinopeptide A, and plasma leucocyte elastase. In 617 patients with claudication followed up for one year, baseline XLFDP was related most strongly to coronary events, relative risk 4.4 (95% CI 1.3-19.0) between top and bottom quintiles. Plasma fibrinogen was the strongest independent predictor of death from coronary disease. XLFDP was the only factor, in addition to age and cigarette smoking, that was independently associated (p = 0.008) with deterioration in peripheral arterial disease. We conclude that, in patients with peripheral arterial disease, plasma concentration of XLFDP, a measure of ongoing fibrin formation and degradation, is a strong predictor of both disease progression and future coronary risk. These results accord with the hypothesis that fibrin formation contributes to progression of coronary and peripheral atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100915     DOI: 10.1016/0140-6736(93)91288-w

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  26 in total

Review 1.  Pathogenesis and pathology of coronary heart disease syndromes.

Authors:  P M Ridker; E M Antman
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

2.  Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis.

Authors:  H Bruunsgaard; P Skinhøj; A N Pedersen; M Schroll; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Evaluation of overall fibrinolytic activity in patients with coronary artery ectasia: global fibrinolytic capacity.

Authors:  Abdullah Dogan; Bahattin Tunc; Oktay Ergene; Mehmet Ozaydin; Cem Nazli; Ahmet Altinbas; Omer Gedikli
Journal:  Int J Cardiovasc Imaging       Date:  2003-12       Impact factor: 2.357

4.  Hypercoagulability and haemodynamic abnormalities in atrial fibrillation.

Authors:  G Y Lip
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

5.  Nonvalvular atrial fibrillation: evidence for a prothrombotic state.

Authors:  S R Kahn; S Solymoss; K M Flegel
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

6.  Supervised walking exercise therapy improves gait biomechanics in patients with peripheral artery disease.

Authors:  Molly N Schieber; Iraklis I Pipinos; Jason M Johanning; George P Casale; Mark A Williams; Holly K DeSpiegelaere; Benjamin Senderling; Sara A Myers
Journal:  J Vasc Surg       Date:  2019-08-20       Impact factor: 4.268

7.  Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation.

Authors:  R M Heppell; K E Berkin; J M McLenachan; J A Davies
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

8.  Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis.

Authors:  S H Zaidi; C C Hui; A Y Cheah; X M You; M Husain; M Rabinovitch
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

9.  African-American ethnicity is associated with higher plasma levels of D-dimer in adults with hypertension.

Authors:  M Khaleghi; U Saleem; R D McBane; T H Mosley; I J Kullo
Journal:  J Thromb Haemost       Date:  2008-10-30       Impact factor: 5.824

Review 10.  [Drug treatment strategies for peripheral obliterative arteriopathy].

Authors:  H Bounameaux; R Wütschert
Journal:  Drugs       Date:  1998       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.